Skip to main content


HER2 therapy

Mark Pegram

  1. Content type: Review

    HER-2/neu status of the primary breast cancer (PBC) is determined by immunohistochemistry and fluorescent in situ hybridization. Because of a variety of technical factors, however, the PBC may not accurately refl...

    Authors: Walter P Carney, Kim Leitzel, Suhail Ali, Rainer Neumann and Allan Lipton

    Citation: Breast Cancer Research 2007 9:207

    Published on:

  2. Content type: Review

    Overexpression of the human epidermal growth factor receptor (HER)-2 oncogenic receptor tyrosine kinase, which occurs in 25% of breast cancers, portends poor clinical outcome and consequently represents an att...

    Authors: Neil Spector, Wenle Xia, Iman El-Hariry, Yossi Yarden and Sarah Bacus

    Citation: Breast Cancer Research 2007 9:205

    Published on:

  3. Content type: Review

    Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor. The majority of patients with metastatic breast cancer who initially respond to trastuzumab develop resistance within on...

    Authors: Rita Nahta and Francisco J Esteva

    Citation: Breast Cancer Research 2006 8:215

    Published on: